Status:

TERMINATED

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Lead Sponsor:

1200 Pharma, LLC

Conditions:

Advanced Solid Tumor

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-01-097 in patients with advanced solid tumors.

Eligibility Criteria

Inclusion

  • Advanced solid tumor
  • Measurable disease, per RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Adequate organ function

Exclusion

  • Has not recovered \[recovery is defined as NCI CTCAE, version 5.0, grade ≤1\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements
  • Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of UCT-01-097
  • Progressive or symptomatic brain metastases
  • Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
  • History of phosphate or calcium disorder
  • History of significant cardiac disease
  • History or current evidence/risk of retinopathy
  • History of myelodysplastic syndrome (MDS) or AML
  • History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded
  • If female, is pregnant or breastfeeding

Key Trial Info

Start Date :

March 3 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 29 2024

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT04761601

Start Date

March 3 2021

End Date

February 29 2024

Last Update

March 13 2024

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

UCLA - JCCC Clinical Research Unit

Los Angeles, California, United States, 90095

2

Torrance Memorial

Torrance, California, United States, 90505

3

Winship Institute of Emory University

Atlanta, Georgia, United States, 30322

4

Fort Wayne Medical Oncology and Hematology

Fort Wayne, Indiana, United States, 46804